{"id":3074,"date":"2016-04-26T06:30:00","date_gmt":"2016-04-26T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-interim-report-january-march-2016\/"},"modified":"2016-04-26T06:30:00","modified_gmt":"2016-04-26T06:30:00","slug":"xvivo-perfusion-interim-report-january-march-2016","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/","title":{"rendered":"XVIVO Perfusion Interim report January \u2013 March 2016"},"content":{"rendered":"
17% GROWTH* EXCL. DURABLE GOODS AND 22% EBITDA MARGIN EXCL. ONE-TIME COSTS<\/strong><\/div>\n<\/p>\n

FIRST QUARTER 2016 (JAN \u2013 MAR)<\/span><\/p>\n<\/p>\n

\u00a0\u2022 Net sales of non-Durable goods** in the quarter amounted to SEK 29.1 (25.1) million, corresponding to an increase of 16 percent in SEK. Sales of non-Durable goods increased by 17 percent in local currency. Net sales in the quarter amounted to SEK 33.5 (31.8) million, corresponding to an increase of 5 percent.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 7.3 (4.5) million, corresponding to an EBITDA margin of 22 percent. One-time expenses of SEK 2.4 million related to the Nasdaq Stockholm main market listing and the public offer for Vivoline have been charged against the quarter. Operating income before depreciation and amortization (EBITDA) amounted to SEK 4.9 (2.9) million, corresponding to an EBITDA margin of 15 percent.
\u2022 Net income amounted to SEK 1.1 (0.0) million, resulting in earnings per share of SEK 0.05 (0.00), affected by amortization and depreciation of SEK 3.1 (2.7) million.
\u2022 Cash flow from operating activities was SEK 5.3 (-5.9) million and the cash at bank increased by SEK 1.5 million to SEK 42.7 million compared to the last quarter of last year.
\u2022 Warm perfusion sales from non-durable goods (STEEN Solution\u2122, products and services related to the use of the XPS\u2122) accounted for 31 (30) percent of the total sales of non-Durable goods. Total sales from warm perfusion (STEEN Solution\u2122, products and services related to the use of the XPS\u2122 and XPS\u2122) accounted for 40 (45) percent of the total sales.
\u2022 During the quarter 3 XPS\u2122 were sold, of which 2 to Europe and 1 to the US. France and Switzerland were new countries that got access to the XPS\u2122 during the quarter.
\u2022 XVIVO Perfusion has been granted a CE mark for a patent-protected product, PrimECC\u00ae<\/sup>, developed to prime the heart-lung machine before open heart surgery. The company will expand the clinical documentation for PrimECC\u00ae<\/sup> through additional clinical studies in 2016.
\u2022 XVIVO Perfusion AB\u2019s shares were admitted for trading on Nasdaq First North Premier 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.
\u2022 Russia\u2019s Federal Service for Supervision on Health Care has approved Perfadex\u00ae<\/sup> and STEEN Solution\u2122 for lung transplantation. This means that Perfadex\u00ae<\/sup> and STEEN Solution\u2122 may be sold for clinical use in Russia.<\/span><\/p>\n<\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER <\/span><\/p>\n<\/p>\n

\u2022 XVIVO Perfusion announces a recommended public offer to the holders of shares and warrants of series 2015\/2016 in Vivoline Medical.
\u2022 Boston\u2019s Brigham and Women\u2019s Hospital is the first clinic in the New England area of USA to sign an XPS\u2122 contract.
\u2022 At the time of publication of this report, 25 clinics have access to the XPS\u2122, including 18 clinics in the US and 6 clinics in Europe.<\/span><\/p>\n<\/p>\n

CONFERENCE CALL<\/span><\/p>\n<\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Tuesday, April 26, 2016. Telephone: +44 (0) 1452 555566, enter code 76364070.<\/span><\/p>\n<\/p>\n

April 26, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span><\/span><\/p>\n<\/p>\n

* Growth in local currencies.
** Durable goods are sales revenues from the XPS\u2122.<\/span><\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
<\/a>Magnus Nilsson, CEO,+ 46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0April 26, 2016\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

17% GROWTH* EXCL. DURABLE GOODS AND 22% EBITDA MARGIN EXCL. ONE-TIME COSTS FIRST QUARTER 2016 (JAN \u2013 MAR) \u00a0\u2022 Net…<\/p>\n","protected":false},"template":"","class_list":["post-3074","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn"],"acf":[],"yoast_head":"\nXVIVO Perfusion Interim report January \u2013 March 2016 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion Interim report January \u2013 March 2016 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"17% GROWTH* EXCL. DURABLE GOODS AND 22% EBITDA MARGIN EXCL. ONE-TIME COSTS FIRST QUARTER 2016 (JAN \u2013 MAR) \u00a0\u2022 Net...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-march-2016\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-march-2016\\\/\",\"name\":\"XVIVO Perfusion Interim report January \u2013 March 2016 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-04-26T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-march-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-march-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-march-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion Interim report January \u2013 March 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion Interim report January \u2013 March 2016 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion Interim report January \u2013 March 2016 - XVIVO","og_description":"17% GROWTH* EXCL. DURABLE GOODS AND 22% EBITDA MARGIN EXCL. ONE-TIME COSTS FIRST QUARTER 2016 (JAN \u2013 MAR) \u00a0\u2022 Net...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/","name":"XVIVO Perfusion Interim report January \u2013 March 2016 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-04-26T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-march-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion Interim report January \u2013 March 2016"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}